Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 794968, 9 pages
Review Article

Beyond the Immune Suppression: The Immunotherapy in Prostate Cancer

1Department of Molecular Medicine, Sapienza University of Rome, 00161 Rome, Italy
2Department of Urology, Sapienza University of Rome, 00161 Rome, Italy
3Department of “Medicina dei Sistemi” Rheumatology, Allergology and Clinical Immunology, University of Rome “Tor Vergata”, 00133 Rome, Italy

Received 28 November 2014; Revised 6 February 2015; Accepted 6 February 2015

Academic Editor: Anshu Agrawal

Copyright © 2015 Ida Silvestri et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Prostate cancer (PCa) is the second most common cancer in men. As well in many other human cancers, inflammation and immune suppression have an important role in their development. We briefly describe the host components that interact with the tumor to generate an immune suppressive environment involved in PCa promotion and progression. Different tools provide to overcome the mechanisms of immunosuppression including vaccines and immune checkpoint blockades. With regard to this, we report results of most recent clinical trials investigating immunotherapy in metastatic PCa (Sipuleucel-T, ipilimumab, tasquinimod, Prostvac-VF, and GVAX) and provide possible future perspectives combining the immunotherapy to the traditional therapies.